Edesa Biotech (EDSA)
NASDAQ:EDSA
Want to see EDSA full AI Analyst Report?
EDSA Stock Chart & Stats
$1.48
>-$0.01(-0.02%)
At close: 4:00 PM EST
$1.48
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$0.72 - $20.32
Previous CloseN/A
Volume1.31K
Average Volume (3M)862.89K
Market Cap
$43.93M
Enterprise Value$54.20M
Total Cash (Recent Filing)$10.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Aug 07, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding8,891,951
10 Day Avg. Volume307,701
30 Day Avg. Volume862,894
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-526.25
Enterprise Value/Ebitda-5.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Clinical SignalsExploratory Phase 2/3 analyses showing mortality reduction and improved kidney outcomes for paridiprubart provide durable scientific validation of the anti-TLR4 approach. Such positive signals can de-risk the program, inform trial design, broaden indication potential, and strengthen long-term pipeline value if confirmed.
Balance Sheet StrengthEffectively zero debt and roughly $12.4M of equity reduce solvency and refinancing risk, giving the company structural financial flexibility. Low leverage supports continued R&D investment and provides a longer runway than highly leveraged peers, improving resilience during multi-year clinical programs.
Governance & IncentivesBoard continuity and shareholder approval of expanded equity incentives strengthen governance and retention. The equity-plan flexibility enables cash conservation, aligns management with long-term shareholder outcomes, and supports consistent leadership through extended clinical development cycles.
Bears Say
Cash BurnSustained negative operating and free cash flow of roughly -$7.6M TTM indicates ongoing funding needs to advance trials. This structural cash burn increases reliance on external financing, risks program delays if capital access tightens, and can lead to dilution or slowed development timelines.
Minimal Revenue & LossesWith negligible product revenue and a ~-$10.4M TTM net loss, the company remains entirely dependent on development outcomes for eventual commercialization. Persistent losses can erode equity over time, constrain R&D if financing is limited, and make long-term operations contingent on successful trials or partnerships.
Dependence On Equity FinancingA business model reliant on equity raises and non‑operating inflows is structurally dilutive and sensitive to capital market conditions. Long-term program funding and strategic flexibility may be impaired during market stress, increasing execution risk and potential shareholder dilution across multi-year development programs.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $0.72 and its highest was $20.32 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $43.93M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Aug 07, 2026 which is in 58 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on May 14, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.23.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Overvalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.63.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 8,891,951 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -10.678%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
EDSA Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $9.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.7%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
193.44%
12-Months-Change
Fundamentals
Return on Equity
-82.34%
Trailing 12-Months
Asset Growth
-24.73%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
21.60% Insiders
1.41% Mutual Funds
24.25% Other Institutional Investors
51.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---